“Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at EGFR ≥20 and Combining With a Nonsteroidal MRA”. Diabzen, vol. 4, no. 17, July 2026, pp. 34-35, https://thediabzen.com/index.php/d/article/view/60.